FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892096510> ?p ?o ?g. }

• W2892096510 abstract "218 Background: Gastroenteropancreatic neuroendocrine tumor (GEPNET) incidence has risen 6-fold over past 3 decades. North American Neuroendocrine Tumor Society estimates that over 100,000 GEPNET patients are currently living in the United States. One of the common quality of life limiting symptom seen in GEPNET patient is diarrhea. Diarrhea in these patients could be due to excessive serotonin production, secondary to post-operative short gut syndrome, steatorrhea from somatostatin analogs, bile acid colitis or intestinal bacterial overgrowth. A novel amino acid based oral rehydration solution (enterade) is currently being evaluated in a Phase II clinical trial for antidiarrheal effects in post bone marrow transplant patients (NCT02919670). We conducted a pilot study of enterade in neuroendocrine tumor (NET's) patients with quality of life limiting diarrhea. Methods: Medical records of all the NET patients given enterade to alleviate symptomatic diarrhea were evaluated. Patients were treated at Markey Cancer Center between May 2017-June 2018. Results: Total 69 NETs patients were treated with enterade. Enterade was administered as 8 Oz bottle BID for 1 a week. Antidiarrheal efficacy data was available on 41 patients at the time of abstract submission. 15 patients had small bowel NETs, 5 had bronchial NETs, 1 had colorectal NETs, 3 had NETs of unknown primary, 3 had gastric NETS, 3 had pancreatic NETs and one had high grade neuroendocrine carcinoma of the prostate. Data regarding primary site was unavailable in 10/41 patients. 21 patients had history of prior bowel resection either for primary neuroendocrine tumor resection or debulking. 25 patients were on somatostatin analogs at the time of initiation of enterade. 31 out of 41 patients reported some reduction in diarrhea frequency. 21 out of these 41 patients reported at least a 50% reduction in diarrhea frequency. Conclusions: 75.6% (31/41) neuroendocrine tumor patients reported improvement in diarrhea frequency with enterade. 51.2% (21/41) reported more than 50% reduction in diarrhea frequency. A prospective Phase II study of enterade in neuroendocrine tumor patients with quality of life limiting diarrhea is currently planned." @default.
• W2892096510 created "2018-09-27" @default.
• W2892096510 creator A5002426047 @default.
• W2892096510 creator A5005448318 @default.
• W2892096510 creator A5016220878 @default.
• W2892096510 creator A5020790520 @default.
• W2892096510 creator A5023436882 @default.
• W2892096510 creator A5034982613 @default.
• W2892096510 creator A5035676150 @default.
• W2892096510 creator A5051388864 @default.
• W2892096510 date "2018-12-01" @default.
• W2892096510 modified "2023-09-23" @default.
• W2892096510 title "The antidiarrheal efficacy of a proprietary amino acid mixture in neuroendocrine tumor (NET) patients." @default.
• W2892096510 doi "https://doi.org/10.1200/jco.2018.36.34_suppl.218" @default.
• W2892096510 hasPublicationYear "2018" @default.
• W2892096510 type Work @default.
• W2892096510 sameAs 2892096510 @default.
• W2892096510 citedByCount "0" @default.
• W2892096510 crossrefType "journal-article" @default.
• W2892096510 hasAuthorship W2892096510A5002426047 @default.
• W2892096510 hasAuthorship W2892096510A5005448318 @default.
• W2892096510 hasAuthorship W2892096510A5016220878 @default.
• W2892096510 hasAuthorship W2892096510A5020790520 @default.
• W2892096510 hasAuthorship W2892096510A5023436882 @default.
• W2892096510 hasAuthorship W2892096510A5034982613 @default.
• W2892096510 hasAuthorship W2892096510A5035676150 @default.
• W2892096510 hasAuthorship W2892096510A5051388864 @default.
• W2892096510 hasConcept C126322002 @default.
• W2892096510 hasConcept C2776297358 @default.
• W2892096510 hasConcept C2779066768 @default.
• W2892096510 hasConcept C2779802037 @default.
• W2892096510 hasConcept C2781025020 @default.
• W2892096510 hasConcept C2781151469 @default.
• W2892096510 hasConcept C71924100 @default.
• W2892096510 hasConcept C90924648 @default.
• W2892096510 hasConceptScore W2892096510C126322002 @default.
• W2892096510 hasConceptScore W2892096510C2776297358 @default.
• W2892096510 hasConceptScore W2892096510C2779066768 @default.
• W2892096510 hasConceptScore W2892096510C2779802037 @default.
• W2892096510 hasConceptScore W2892096510C2781025020 @default.
• W2892096510 hasConceptScore W2892096510C2781151469 @default.
• W2892096510 hasConceptScore W2892096510C71924100 @default.
• W2892096510 hasConceptScore W2892096510C90924648 @default.
• W2892096510 hasLocation W28920965101 @default.
• W2892096510 hasOpenAccess W2892096510 @default.
• W2892096510 hasPrimaryLocation W28920965101 @default.
• W2892096510 hasRelatedWork W2034758905 @default.
• W2892096510 hasRelatedWork W2094794971 @default.
• W2892096510 hasRelatedWork W2131492952 @default.
• W2892096510 hasRelatedWork W2244923374 @default.
• W2892096510 hasRelatedWork W2590831073 @default.
• W2892096510 hasRelatedWork W2792443624 @default.
• W2892096510 hasRelatedWork W2794290503 @default.
• W2892096510 hasRelatedWork W2892096510 @default.
• W2892096510 hasRelatedWork W3027098235 @default.
• W2892096510 hasRelatedWork W3158139671 @default.
• W2892096510 isParatext "false" @default.
• W2892096510 isRetracted "false" @default.
• W2892096510 magId "2892096510" @default.
• W2892096510 workType "article" @default.